Boxabl Appoints Larry King As CFO, Heather Clayton As CAO; Stock Down In Pre-Market

BOXABL (BXBL) began trading on Nasdaq after a SPAC merger, valued at $3.5 billion with 350 million shares at $10 each. The company has raised over $230 million and produced 800 modular homes, expanding into residential, multifamily, and commercial housing. Management plans to grow production and diversify offerings. The company became public through a merger with FG Merger II Corp, with risks including volatility and dilution.

BOXABL Inc. (BXBL) signed a multiyear deal with LC Vegas Acquisitions, LLC to supply up to 1,500 homes over three years. The agreement, BOXABL's largest to date, highlights demand for factory-built housing solutions. Purchases are subject to project schedules, regulatory approvals, and other conditions. BOXABL's modular homes aim to address affordability and construction speed.

BOXABL Inc. (BXBL) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-99.5 13 ex99-5.htm EX-99.5 Exhibit 99.5 Unaudited Condensed Consolidated Balance Sheets as of March 31, 2026 (unaudited) and December 31, 2025 (audited) F-2 Unaudited Condensed Consolidated Statements of Comprehensive Loss for the Three Months Ended March 31, 2026 and 2025 F-3

Galp Energia and Equinor have been awarded an offshore oil block in Brazil's Santos Basin. Galp will own 30% of the Rodocrosita block, with Equinor operating the remaining 70%. The companies may explore synergies with the adjacent Bacalhau project, which is ramping up production and will contribute 40,000 barrels per day to Galp once fully operational.

Pinterest (PINS) appointed Amazon's James Dibbo as its new CFO. The company's stock has shown mixed performance, with a recent 7-day return of 7.52% but a 1-year return of -36.11%. Analysts have varying views on its valuation, with some seeing it as undervalued at $20.31 per share compared to a fair value estimate of $29.05, while others note its high P/E ratio of 46.2x.

Shanghai Allist Pharmaceuticals (SS:688578) shares dropped 20% after its U.S. partner ArriVent Biopharma (NASDAQ:AVBP) reported that a late-stage trial of lung cancer drug firmonertinib failed to meet its primary endpoint. The drug did not show a statistically significant improvement in progression-free survival for patients with non-small cell lung cancer.